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AbstrAct
Background The lack of effective therapies for heart 
failure with preserved ejection fraction (HFpEF) reflects an 
incomplete understanding of its pathogenesis.
Design We analysed baseline risk factors for incident 
HFpEF, heart failure with reduced ejection fraction (HFrEF) 
and valvular heart failure (VHF) in a community-based 
cohort.
Methods We recruited 2101 men and 1746 women ≥60 
years of age with hypertension, diabetes, ischaemic heart 
disease (IHD), abnormal heart rhythm, cerebrovascular 
disease or renal impairment. Exclusion criteria were 
known heart failure, left ventricular ejection fraction <50% 
or valve abnormality >mild in severity. Median follow-up 
was 5.6 (IQR 4.6–6.3) years.
Results Median time to heart failure diagnosis in 162 
participants was 4.5 (IQR 2.7–5.4) years, 73 with HFpEF, 
53 with HFrEF and 36 with VHF. Baseline age and amino-
terminal pro-B-type natriuretic peptide levels were 
associated with HFpEF, HFrEF and VHF. Pulse pressure, 
IHD, waist circumference, obstructive sleep apnoea and 
pacemaker were associated with HFpEF and HFrEF; atrial 
fibrillation (AF) and warfarin therapy were associated 
with HFpEF and VHF and peripheral vascular disease and 
low platelet count were associated with HFrEF and VHF. 
Additional risk factors for HFpEF were body mass index 
(BMI), hypertension, diabetes, renal dysfunction, low 
haemoglobin, white cell count and β-blocker, statin, loop 
diuretic, non-steroidal anti-inflammatory and clopidogrel 
therapies, for HFrEF were male gender and cigarette 
smoking and for VHF were low diastolic blood pressure 
and alcohol intake. BMI, diabetes, low haemoglobin, 
white cell count and warfarin therapy were more strongly 
associated with HFpEF than HFrEF, whereas male gender 
and low platelet count were more strongly associated with 
HFrEF than HFpEF.
Conclusions Our data suggest a major role for 
BMI, hypertension, diabetes, renal dysfunction, and 
inflammation in HFpEF pathogenesis; strategies directed 
to prevention of these risk factors may prevent a sizeable 
proportion of HFpEF in the community.
Trial registration number NCT00400257, NCT00604006 
and NCT01581827.
InTRoDuCTIon
Heart failure (HF) is a major cause of prema-
ture morbidity and mortality with a lifetime 
risk of 20%–46%,1 and preventive strategies 
focused on pathogenic mechanisms are 
required. It is a complex clinical syndrome 
that results from any structural or functional 
impairment of ventricular filling or ejection 
of blood that may result from disorders of the 
pericardium, myocardium, endocardium, 
heart valves, great vessels or metabolic abnor-
malities, but most patients with HF have symp-
toms due to impaired left ventricular (LV) 
structure or function.2 Apart from HF due 
primarily to valvular dysfunction (valvular HF 
(VHF)), which can often be corrected by valve 
Key questions
What is already known about this subject?
 ► Heart failure (HF) is a heterogeneous condition 
that encompasses HF with preserved (HFpEF) and 
reduced ejection fraction (HFrEF) and valvular HF 
(VHF).
 ► Although there are effective therapies for HFrEF and 
VHF, there are no therapies that improve the prog-
nosis of HFpEF.
 ► In addition, the mechanisms of HFpEF are incom-
pletely understood.
What does this study add?
 ► This study reports the risk factors for HFpEF, HFrEF 
and VHF identified in a community-based cohort 
many years before diagnosis of HF.
 ► Our data suggest a major role for body mass index, 
hypertension, diabetes, renal dysfunction and in-
flammation in HFpEF pathogenesis.
How might this impact on clinical practice?
 ► Strategies that prevent increased body mass index, 
hypertension, diabetes, renal dysfunction and in-
flammation may prevent HFpEF.
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surgery, HF is usually categorised according to the LV ejec-
tion fraction (LVEF), with HF with LVEF ≥50% referred to 
as HF with preserved ejection fraction (HFpEF) and HF 
with LVEF <50% referred to as HF with reduced ejection 
fraction (HFrEF).3 Separation of non-valvular HF into 
HFpEF and HFrEF is important because although there 
are many therapies that improve the prognosis of HFrEF, 
there are as yet no therapies that improve the prognosis 
of HFpEF.4 More recently, HFrEF has been subdivided 
into mid-range (LVEF 40%–49%) and reduced ejection 
fraction (LVEF <40%) because the therapeutic improve-
ment in prognosis of patients with HFrEF was demon-
strated in those with LVEF <35%.4 HFpEF accounts for 
approximately half of HF in the community,5 and the lack 
of therapies that improve the prognosis of this condition 
reflects an incomplete understanding of its pathogenesis.
Only limited information is available concerning the 
risk factors for incident HFpEF and HFrEF.6–10 More-
over, previous studies of HF incidence have either not 
mentioned valvular disease,6 9 or included VHF within 
the HFrEF and HFpEF classifications.7 8 11 To gain insight 
into the different pathogenic mechanisms of HFpEF, 
HFrEF and VHF, we analysed risk factors for incident HF 
in participants of the SCReening Evaluation of the Evolu-
tion of New HF (SCREEN-HF) study, a prospective cohort 
study of men and women recruited from the commu-
nity ≥60 years of age without HF, but with risk factors 
for HF. We hypothesised that the risk factor profiles of 
HFpEF, HFrEF and VHF may suggest distinct pathophys-
iological mechanisms.
MeTHoDs
study population
The SCREEN-HF study was a community-based evalu-
ation of the use of serum amino-terminal pro-B-type 
natriuretic peptide (NT-proBNP) to identify individuals 
with cardiac dysfunction (as assessed by echocardiog-
raphy) and increased risk of HF and other cardiovas-
cular events, which has been described elsewhere.12 We 
report here the follow-up of the SCREEN-HF cohort to 
detect incident HF. The flow chart for participant recruit-
ment and follow-up is shown in figure 1. In summary, 
44 000 members of private health fund Bupa, resident 
in Melbourne or Shepparton, Victoria, Australia, were 
invited to participate. Inclusion criteria were age ≥60 
years with one or more of self-reported treatment for 
hypertension or diabetes for ≥2 years, myocardial infarc-
tion (MI) or other ischaemic heart disease (IHD) or 
valvular heart disease, irregular or rapid heart rhythm, 
cerebrovascular disease or renal impairment. Exclusion 
criteria were previously diagnosed HF, previous valve 
surgery or documented valve abnormality graded >mild 
or LVEF <50% on previous echocardiography or other 
cardiac imaging. Documentation of previous cardiac 
imaging was requested from hospitals and from the 
participant's primary care provider, physician and cardi-
ologist. However, for this community-based cohort, most 
participants had not had cardiac imaging before enrol-
ment. Recruitment commenced in May 2007 and was 
completed in January 2010.
Of the 4054 individuals enrolled at the baseline visit 
(visit 1), 3847 met the inclusion and exclusion criteria, 
of which 92% were Bupa members. The baseline visit 
was conducted by a study research nurse who consented, 
interviewed and examined the participant and collected 
a non-fasting blood sample for measurement of electro-
lytes, creatinine, urea, glucose, full blood examination 
and NT-proBNP. Details of symptoms, interim clinical 
events and medication were collected, echocardiog-
raphy was performed and the participant examined for 
signs of HF during visits 2 and 3. Additionally, details 
of interim clinical events, symptoms and medication 
were collected by telephone interview approximately 
4 and 7 years following enrolment. Follow-up was 
completed between 2013 and 2015. The SCREEN-HF 
study was approved by the Alfred Human Research 
Ethics Committee and written informed consent was 
obtained from all participants. The study was registered 
at  ClinicalTrials. gov NCT00400257, NCT00604006 and 
NCT01581827.
study variables
Baseline clinical factors
Age, sex and past medical history, which included 
IHD (MI, angina, coronary revascularisation), valvular 
or other heart disease or heart surgery, hyperten-
sion, respiratory disease, renal impairment, cardiac 
arrhythmia including atrial fibrillation (AF), cerebro-
vascular disease, diabetes, peripheral vascular disease 
(PVD, including aortic and carotid disease), obstruc-
tive sleep apnoea (OSA) and pacemaker use, based on 
self-report, were recorded. Of the 3294 participants with 
hypertension at enrolment, 99% were receiving antihy-
pertensive therapy. Of the 703 participants with diabetes 
at enrolment, 74% were receiving oral antidiabetic 
and/or insulin therapy and the remainder were treated 
with diet alone. Self-reported details of lifestyle factors 
included smoking history and alcohol intake. Height, 
weight and waist circumference were measured, and 
blood pressure (BP) and heart rate were measured with 
an automatic BP monitor (A&D Medical, Kensington, 
Victoria) after sitting for at least 5 min. Two BP readings 
were taken 3 min apart and the present analysis uses the 
mean of these two readings. Participants brought details 
of their medications to the baseline study visit, which 
were recorded.
Body mass index (BMI) was calculated as the ratio of 
weight to height squared (kg/m2). Estimated glomerular 
filtration rate (eGFR) was calculated using the Modifi-
cation of Diet in Renal Disease study equation.13 Serum 
NT-proBNP was measured by electrochemiluminescence 
immunoassay using an Elecsys instrument (Roche Diag-
nostics, Basel, Switzerland) with a lower limit of detection 
of 0.6 pmol/L.
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HF and other events
In order to capture all incident cases of HF, a participant 
was referred to their cardiologist or to a SCREEN-HF 
study cardiologist if they reported symptoms consistent 
with HF or if signs consistent with HF were detected 
during a study visit, and information was requested 
from the participant's primary care provider, physician 
and cardiologist. All participant files were reviewed by 
a cardiovascular physician and documentation of all 
deaths and other events was requested from hospitals 
and the participant's primary care provider, physician 
and cardiologist. All diagnoses of HF and suspicion of 
HF were submitted to adjudication by two HF special-
ists according to European Society of Cardiology (ESC) 
criteria of 2012.3 The adjudicators were provided with 
all available information including reports of imaging 
studies; however, they were not informed of the base-
line NT-proBNP level, although they were informed 
of any NT-proBNP and BNP levels measured as part of 
usual care. When one adjudicator made a diagnosis of 
HF and the other did not, a third HF specialist adju-
dicated on the presence or absence of HF. Based on 
cardiac imaging at the time of or after HF diagnosis, 
non-valvular HF was categorised as either HFpEF 
Figure 1 Consolidated Standards of Reporting Trials flow diagram describing participant recruitment and follow-up in the 
SCReening Evaluation of the Evolution of New HF (SCREEN-HF) study. Durations of follow-up for visits and phone review are 
shown as medians (IQR).
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(LVEF ≥50%) or HFrEF (LVEF <50%), and VHF was 
diagnosed when HF was attributed to valvular dysfunc-
tion graded as severe.
statistical analysis
Continuous variables were summarised as means (SD) or 
medians (IQR), depending on their distribution exhib-
iting skewness. Categorical variables were summarised 
as numbers (percentages). Comparisons between partic-
ipant groups were performed with the use of Student's 
t-test for continuous variables that were approximately 
normally distributed with or without log transformation, 
or with the use of Mann-Whitney U test. Categorical vari-
ables were compared with the use of Χ2 test or Fisher's 
exact test.
Data were complete for the 162 participants who devel-
oped HF, except for one with missing BP and heart rate. 
Of 3685 participants who did not develop HF during 
follow-up, the maximum number with missing data 
was 13 for platelet count. In multivariable analysis, the 
maximum number with missing data was 21. Participants 
were omitted from particular analyses if the required vari-
ables were missing.
Except for the analysis of survival after HF diagnosis, 
data were censored at the date of last contact or devel-
opment of HF or death, whichever came first. Inci-
dence rate data were analysed using Poisson regression. 
Survival after diagnosis of HFpEF, HFrEF or VHF was 
compared using Kaplan-Meier curves and a log-rank 
test. Cumulative incidence curves were constructed with 
the use of the non-parametric cumulative incidence 
function of Fine and Gray,14 with non-HF-related death 
and other categories of HF as competing risks. HRs for 
univariate risk factors for HF outcomes were calculated 
using a semiparametric proportional hazards model for 
the subdistribution of competing risk, with non-HF-re-
lated death and other categories of HF as competing 
risks.14 Martingale residuals were calculated to test for 
non-linearity of continuous variables, and Schoenfeld 
residuals were calculated to assess whether propor-
tional hazards assumptions were satisfied. Although log 
NT-proBNP levels were normally distributed, Martingale 
residuals revealed non-linearity for the association of log 
NT-proBNP with log-hazard, and therefore NT-proBNP 
levels were divided into quintiles for the calculation of 
HRs. Multivariable models were constructed by back-
ward selection using Akaike information criteria and 
competing models compared using Bayesian informa-
tion criteria. The HR associating each risk factor with 
HFpEF versus HFrEF were formally tested for equality 
using the method of Lunn and McNeil.15 C statistics were 
estimated from time-dependent areas under receiver 
operating characteristic curves for censored event times 
with competing risks.16 A two-sided p value of <0.05 was 
considered to indicate statistical significance. Data were 
analysed with SPSS software V.22 and with R software 
V.1.0.153.
ResulTs
HF diagnosis
The median follow-up of the 3847 participants was 5.6 
(IQR 4.6–6.3) years, with 271 non-HF-related deaths 
during follow-up. Files from 193 participants were 
submitted to adjudication, with 77% agreement between 
the two adjudicators with respect to the presence or 
absence of HF according to ESC criteria of 20123; 45 
cases for which one adjudicator diagnosed HF and one 
adjudicator was equivocal were submitted to adjudication 
by a third HF specialist. Of the 162 participants with a HF 
diagnosis confirmed by two HF specialists, 63 were diag-
nosed on hospitalisation. Excluding hospitalisations for 
valve surgery, a further 44 participants were hospitalised 
for HF after HF diagnosis. Of the 99 participants diag-
nosed with HF in the ambulant setting, 76 were initially 
diagnosed by their cardiologist or primary care provider 
and 23 were initially diagnosed by SCREEN-HF investiga-
tors. When age on enrolment was categorised according 
to <70, 70–79 and ≥80 years, there were significant differ-
ences in HF incidence rate between the three age groups, 
but no difference between men and women (see online 
supplementary figure 1).
All HF cases had cardiac imaging either at the time of 
HF diagnosis or after HF diagnosis; 121 within 30 days of 
HF diagnosis and the remaining 41 were imaged a median 
of 177 (IQR 64–340) days post-HF diagnosis; however, 
all but four participants imaged >30 days post-HF diag-
nosis had echocardiography before HF diagnosis. The 
predominant modality for LVEF determination at the 
time of HF diagnosis or after HF diagnosis was echocar-
diography (n=150), but also included left ventriculogram 
(n=10) and myocardial perfusion scan (n=2). Of the 162 
HF cases, 73 were HFpEF, 53 were HFrEF and 36 were 
VHF. We did not subclassify participants with HFrEF 
as mid-range (LVEF 40%–49%) or more severe HFrEF 
(LVEF <40%) because LVEF assessment was only qualita-
tive for 16 of the 53 participants who developed HFrEF; 
of 37 reports with quantitative LVEF assessment, 28 (76 
%) reported LVEF <40%.
The cumulative incidences of total HF, HFpEF, HFrEF 
and VHF are shown in figure 2. The median time to HF 
diagnosis was 4.5 (IQR 2.7–5.4) years for all 162 partic-
ipants with HF, 4.5 (2.9–5.5) years for participants who 
developed HFpEF, 4.8 (2.3–5.4) years for those who 
developed HFrEF and 4.2 (2.9–5.2) years for those who 
developed VHF.
The 36 participants who developed VHF included 1 
with aortic regurgitation, 22 with aortic stenosis and 13 
with mitral regurgitation that included 3 with acute onset 
due to endocarditis of the mitral valve (n=1) or chordal 
rupture (n=2). Of the 36 participants who developed 
VHF, 31 had subsequent valve surgery. One participant 
with HFrEF had valve surgery at the time of coronary 
artery bypass graft surgery. Mortality following HF diag-
nosis was similar for HFpEF, HFrEF and VHF (see online 
supplementary figure 2).
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Baseline clinical variables
Baseline data for participants who developed HF during 
follow-up, and those who did not, are shown in table 1. 
In comparison with participants who did not develop HF 
during follow-up, participants who developed HF were 
older, with higher pulse pressure (PP), lower diastolic 
BP (DBP), lower heart rate and higher BMI and waist 
circumference, and a higher prevalence of diabetes, prior 
MI and coronary revascularisation, PVD, AF, pacemaker, 
OSA and smoking. Participants who developed HF also 
had higher NT-proBNP levels, lower eGFR, lower haemo-
globin, higher white cell count (WCC) and lower platelet 
count, and were more likely to be taking β-blocker, ACE 
inhibitor, statin, loop diuretic, non-steroidal anti-inflam-
matory drug (NSAID), clopidogrel and warfarin thera-
pies.
There were also differences in baseline variables 
between participants who developed HFpEF, HFrEF 
or VHF (table 2). In comparison with participants who 
developed HFrEF during follow-up, participants who 
developed HFpEF were more likely to be female, have 
higher BMI, be diabetic, have AF and to have lower 
haemoglobin, higher WCC and higher platelet count.
Risk factors for incident HFpeF, HFreF and VHF
Baseline variables with statistically significant association 
with incident HFpEF, HFrEF or VHF in univariate analysis 
are shown in figure 3, and univariate HRs for the associa-
tion of total HF, HFpEF, HFrEF and VHF with all baseline 
variables are shown in the online supplementary table 1. 
Age and NT-proBNP levels were associated with HFpEF, 
HFrEF and VHF. PP, IHD, waist circumference, OSA and 
pacemaker were associated with HFpEF and HFrEF; AF 
and warfarin therapy were associated with HFpEF and 
VHF and PVD and low platelet count were associated with 
HFrEF and VHF. Additional risk factors for HFpEF were 
BMI, diabetes, low eGFR, low haemoglobin, WCC and 
β-blocker, statin, loop diuretic, NSAID and clopidogrel 
therapies, for HFrEF were male gender and cigarette 
smoking, and for VHF were low DBP and alcohol intake. 
When HR were compared between HFpEF and HFrEF, 
BMI (p=0.003), diabetes (p=0.009), AF (p=0.009), low 
haemoglobin (p=0.001), WCC (p=0.002) and warfarin 
therapy (p=0.025) were more strongly associated with 
HFpEF than HFrEF, whereas male gender (p<0.0001) 
and low platelet count (p=0.004) were more strongly 
associated with HFrEF than HFpEF.
Although not associated with incident HFpEF in univar-
iate analysis, hypertension was associated with increased 
HR and calcium channel blocker therapy was associated 
reduced HR for incident HFpEF in multivariable anal-
ysis, together with age, NT-proBNP, BMI, diabetes, MI, 
AF and low haemoglobin (table 3). In addition to age 
and NT-proBNP, male gender, waist circumference and 
MI were associated with incident HFrEF in multivariable 
analysis. NT-proBNP, low DBP and alcohol intake were 
associated with incident VHF in multivariable analysis.
Many variables associated with incident HF in univariate 
analyses, including AF, and loop diuretic and β-blocker 
therapies were associated with increased NT-proBNP 
levels, whereas other variables associated with incident 
HF, such as male gender, diabetes, BMI, waist circumfer-
ence and increased alcohol intake were associated with 
lower NT-proBNP levels (online supplementary table 2 
and 3).
There were several instances of non-proportional 
hazards due to statistically significant (p<0.0001) inter-
actions between risk factors and duration of follow-up, 
thereby indicating that the HR for the risk factor varied 
according to the duration of follow-up. In exploratory 
analyses, when follow-up was split into two periods, 
proportional hazards existed within each period (online 
supplementary table 4).
DIsCussIon
We found a wide range of risk factors for incident HFpEF, 
HFrEF and VHF in the SCREEN-HF cohort. To obtain 
information about the early stages of HF pathogen-
esis, we excluded individuals with known LVEF <50%, 
previous valve surgery or documented valve abnormality 
graded >mild on enrolment, and the median time to HF 
diagnosis was 4–5 years after enrolment. Moreover, the 
majority of HF diagnoses and LVEF assessments in the 
SCREEN-HF study were made in the ambulant setting, in 
contrast to previous studies where HF diagnosis or LVEF 
assessment was based on hospitalisation.6–9 The associa-
tion of incident HFpEF, HFrEF and VHF with increased 
baseline levels of NT-proBNP, a marker of cardiomyocyte 
stretch predominantly released from the ventricles,17 
suggests that the mechanisms of HF pathogenesis were 
in play at the time of enrolment many years before HF 
diagnosis. Thus, the risk factors for HF identified in 
the SCREEN-HF cohort may suggest mechanisms of HF 
Figure 2 Cumulative incidence of total heart failure (total 
HF), heart failure with preserved (HFpEF) and reduced 
ejection fraction (HFrEF) and valvular heart failure (VHF). 
Cumulative incidence curves were constructed with the use 
of the non-parametric cumulative incidence function of Fine 
and Gray, with non-HF-related death and other categories of 
HF as competing risks.14
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Table 1 Baseline characteristics of subjects who developed new-onset heart failure and of subjects without heart failure 
during follow-up
HF (n, %) n=162 No HF (n, %) n=3685 P values
Age at enrolment (years) 75 (70, 79) 69 (65, 75) <0.0001
Male 98 (60%) 2003 (54%) 0.13
SBP (mm Hg) 143±19 141±18 0.06
DBP (mm Hg) 79±11 81±10 0.019
PP (mm Hg) 65±16 60±15 <0.0001
Heart rate (bpm) 68 (61, 76) 70 (63, 79) 0.013
BMI (kg/m2) 29 (26, 32) 28 (25, 31) <0.0001
Waist circumference (cm) 104±13 100±19 0.0035
Hypertension 145 (90%) 3149 (85%) 0.17
Diabetes 44 (27%) 659 (18%) 0.0048
Myocardial infarction 37 (23%) 354 (10%) <0.0001
Coronary revascularisation 42 (26%) 534 (14%) 0.0002
Stroke/TIA 21 (13%) 400 (11%) 0.37
PVD 15 (9%) 110 (3%) 0.0002
AF 37 (23%) 356 (10%) <0.0001
Pacemaker 7 (4.3%) 59 (1.6%) 0.020
OSA 21 (13%) 258 (7%) 0.0078
Smoker (current or former) 93 (57%) 1796 (49%) 0.037
Alcohol>2 drinks/day* 39 (24%) 723 (20%) 0.19
Biochemistry and haematology
NT-proBNP (pmol/L) 36 (20, 75) 12 (6, 22) <0.0001
eGFR (mL/min/1.73 m2) 67±18 73±17 <0.0001
Haemoglobin (g/dL) 13.7±1.6 14.0±1.3 0.013
WCC (x109/L) 7.6 (6.3, 8.6) 7.1 (6.1, 8.2) 0.030
Platelets (x109/L) 218 (180, 253) 229 (195, 267) 0.013
Medication
β-Blocker 61 (38%) 828 (22%) <0.0001
ACE inhibitor 62 (38%) 1125 (31%) 0.045
ARB 70 (43%) 1735 (47%) 0.34
ACE inhibitor or ARB 124 (77%) 2726 (74%) 0.52
CCB 51 (31%) 998 (27%) 0.24
Statin 97 (60%) 1896 (51%) 0.037
Thiazide diuretic 48 (30%) 1134 (31%) 0.79
Loop diuretic 19 (11.7%) 90 (2.4%) <0.0001
Aspirin 73 (45%) 1530 (42%) 0.37
NSAID 23 (14.2%) 301 (8.2%) 0.013
Clopidogrel 19 (11.7%) 221 (6.0%) 0.0069
Warfarin 20 (12.3%) 158 (4.3%) <0.0001
Data shown as mean±SD, median (IQR) or n (%).
*Refers to consumption of more than two standard drinks on any day. 
AF, atrial fibrillation; ARB, angiotensin II type 1 receptor blocker; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure 
with reduced ejection fraction; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; NSAID, non-steroidal anti-inflammatory drug; 
OSA, obstructive sleep apnoea; PP, pulse pressure; PVD, peripheral vascular disease; SBP, systolic blood pressure; TIA, transient ischaemic 
attack; VHF, valvular heart failure; WCC, white cell count. 
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Table 2 Baseline characteristics of subjects who developed HFpEF, HFrEF or VHF during follow-up
HFpEF n=73 HFrEF n=53 VHF n=36
P values HFpEF 
vs HFrEF
P values HFpEF 
vs VHF
P values HFrEF 
vs VHF
Age at enrolment (years) 76 (71–79) 74 (71–79) 72 (68–79) 0.52 0.11 0.26
Male 33 (45%) 43 (81%) 22 (61%) <0.0001 0.15 0.052
SBP (mm Hg) 144±19 145±19 141±17 0.84 0.42 0.34
DBP (mm Hg) 80±10 80±13 76±10 0.96 0.08 0.14
PP (mm Hg) 64±16 65±15 65±17 0.81 0.87 0.96
Heart rate (bpm) 68 (62, 75) 69 (61, 79) 67 (60, 79) 0.70 0.82 0.63
BMI (kg/m2) 31 (28, 35) 29 (26, 31) 28 (24, 31) 0.005 <0.0001 0.10
Waist circumference (cm) 107±12 104±14 98±12 0.30 0.0007 0.029
Hypertension 68 (93%) 47 (89%) 30 (83%) 0.52 0.17 0.54
Diabetes 30 (41%) 10 (19%) 4 (11%) 0.011 0.0018 0.39
Myocardial infarction 19 (26%) 16 (30%) 2 (6%) 0.69 0.010 0.006
Coronary
revascularisation
20 (27%) 16 (30%) 6 (17%) 0.84 0.24 0.21
Stroke/TIA 13 (18%) 5 (9%) 3 (8%) 0.21 0.25 1.00
PVD 4 (5%) 7 (13%) 4 (11%) 0.20 0.44 1.0
AF 23 (32%) 6 (11%) 8 (22%) 0.0097 0.37 0.24
Pacemaker 4 (5%) 3 (6%) 0 (0%) 1.0 0.30 0.27
OSA 11 (15%) 8 (15%) 2 (6%) 1.00 0.21 0.19
Smoker (current or former) 38 (52%) 34 (64%) 21 (58%) 0.20 0.55 0.66
Alcohol>2 drinks/day* 11 (15%) 15 (28%) 13 (36%) 0.079 0.025 0.49
Biochemistry and
haematology
  NT-proBNP (pmol/L) 37 (23, 70) 38 (20, 80) 32 (14, 72) 0.62 0.25 0.47
  eGFR (mL/min/1.73 m2) 65±17 68±18 69±19 0.34 0.27 0.82
  Haemoglobin (g/dL) 13.3±1.5 14.2±1.6 13.8±1.5 0.0015 0.12 0.20
  WCC (x109/L) 8.2 (6.7, 9.2) 7.1 (6.1, 7.9) 7.3 (5.8, 8.3) 0.0057 0.019 0.86
  Platelets (x109/L) 233 (188, 277) 210 (179, 235) 204 (171, 236) 0.0070 0.063 0.58
Medication
  β-Blocker 34 (47%) 16 (30%) 11 (31%) 0.069 0.15 1.0
  ACE inhibitor 24 (33%) 22 (42%) 16 (44%) 0.35 0.29 0.83
  ARB 39 (53%) 19 (36%) 12 (33%) 0.070 0.066 0.83
  ACE inhibitor or ARB 58 (79%) 40 (75%) 26 (72%) 0.67 0.47 0.81
  CCB 19 (26%) 21 (40%) 11 (31%) 0.12 0.65 0.50
  Statin 48 (66%) 30 (57%) 19 (53%) 0.35 0.21 0.83
  Thiazide diuretic 27 (37%) 12 (23%) 9 (25%) 0.12 0.28 0.80
  Loop diuretic 13 (17.8%) 4 (7.5%) 2 (5.6%) 0.12 0.14 1.0
  Aspirin 30 (41%) 28 (53%) 15 (42%) 0.21 1.0 0.39
  NSAID 11 (15%) 8 (15%) 4 (11%) 1.0 0.77 0.76
  Clopidogrel 10 (13.7%) 7 (13.2%) 2 (5.6%) 1.0 0.33 0.30
  Warfarin 13 (17.8%) 2 (3.8%) 5 (13.9%) 0.024 0.79 0.11
Data shown as mean±SD, median (IQR) or n (%).
*Refers to consumption of more than  two standard drinks on any day.
AF, atrial fibrillation; ARB, angiotensin II type 1 receptor blocker; BMI, body mass index; CCB, calcium channel blocker; DBP, 
diastolic blood pressure; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
heart failure with reduced ejection fraction; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; NSAID, non-steroidal anti-
inflammatory drug; OSA, obstructive sleep apnoea; PP, pulse pressure; PVD, peripheral vascular disease; SBP, systolic blood 
pressure; TIA, transient ischaemic attack; VHF, valvular heart failure; WCC, white cell count.
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pathogenesis and potential strategies for its prevention 
and treatment.
Age, male gender, coronary disease, hypertension, PP, 
diabetes, AF, smoking, BMI, valvular heart disease, LV 
hypertrophy and black race are established risk factors 
for incident HF as a broad clinical syndrome.18 19 More-
over, previously reported risk factors for valvular dysfunc-
tion include rheumatic heart disease, age, gender, 
tobacco use, hypercholesterolaemia, hypertension, type 
2 diabetes, MI, cardiomyopathies, inflammatory diseases, 
drugs and radiation.20 21 Few studies have examined the 
risk factors for incident HFpEF and HFrEF separately.6–10 
A pooled analysis of HFpEF (LVEF >45%) and HFrEF 
(LVEF ≤45%) cohorts found that age, SBP, BMI, antihy-
pertensive treatment, diabetes, alcohol use and previous 
MI were risk factors for HFpEF; the same risk factors 
were associated with HFrEF, in addition to male gender, 
DBP, heart rate, smoking, previous stroke, left ventricular 
hypertrophy and left bundle branch block.10 In addition, 
Brouwers et al reported NT-proBNP level was a risk factor 
for both HFpEF (LVEF ≥50%) and HFrEF (LVEF ≤40%) 
in multivariable analysis; cystatin C level was a risk factor 
for HFpEF, and troponin level was a risk factor for HFrEF, 
whereas AF was associated with reduced HFrEF risk.9
In contrast to previous studies of risk factors for inci-
dent HFpEF and HFrEF that either did not mention 
valvular disease,6 9 or included VHF within the HFpEF 
and HFrEF categories,7 8 11 we separated VHF from 
HFpEF and HFrEF. In addition, we provide information 
about waist circumference, coronary revascularisation, 
PVD, AF, pacemaker, OSA, eGFR, haemoglobin, WCC, 
platelet count and cardiovascular therapies as risk 
factors for HFpEF, HFrEF and VHF. The association of 
age, male gender, IHD, NT-proBNP and smoking with 
incident HFrEF in the SCREEN-HF cohort was in agree-
ment with previous studies.8–10 Risk factors common to 
HFrEF and HFpEF were age, NT-proBNP, IHD, PP, waist 
circumference, OSA and pacemaker. Increased PP is a 
marker of increased arterial stiffness that may, through 
altered ventriculo-arterial coupling, simultaneously 
increase systolic load and reduce DBP, thereby compro-
mising both cardiac output and myocardial perfusion.22 
Waist circumference, but not BMI, was a risk factor for 
HFrEF; this association was retained in multivariable 
analysis after adjusting for gender, and central obesity 
may have contributed to the pathogenesis of HFrEF, 
and to OSA. The mechanism of the association between 
lower baseline platelet count and incident HFrEF and 
VHF is unknown and may reflect increased platelet 
consumption. The association of AF and warfarin 
therapy with incident HFpEF and VHF may indicate a 
role for atrial arrhythmias in HF pathogenesis. However, 
given the higher NT-proBNP levels in participants with 
AF, it is also possible that AF was the result of subclinical 
cardiac dysfunction present on enrolment. The associa-
tion of low DBP, but not PP, with incident VHF, together 
with NT-proBNP level, may reflect, in part, unrecognised 
valvular dysfunction on enrolment.
Figure 3 Forest plots showing univariate HRs and 95% CIs for risk factors for incident heart failure (HF) with preserved 
(HFpEF) and reduced ejection fraction (HFrEF) and valvular HF (VHF), where a risk factor was significantly associated with 
at least one category of HF; HRs significantly different from 1 (p<0.05) are shown in red. HRs for all risk factors for total HF, 
HFpEF, HFrEF and VHF are shown in the online supplementary table 1. BMI, body mass index; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; NSAID, non-steroidal 
anti-inflammatory drug; PP, pulse pressure; PVD, peripheral vascular disease; WCC, white cell count. Alcohol>2 drinks/day 
refers to consumption of more than two standard drinks on any day. HRs were calculated using a semiparametric proportional 
hazards model for the subdistribution of competing risk, with non-HF-related death and other categories of HF as competing 
risks.14
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A key finding of our study was the number of risk factors 
that suggest a major role for increased BMI in the patho-
genesis of HFpEF. The contribution of increased BMI 
to type 2 diabetes and hypertension is well recognised. 
Obesity is not associated with lower haemoglobin levels in 
the general population,23 and therefore does not explain 
the association of HFpEF with lower haemoglobin levels. 
However, the association of NT-proBNP levels and 
reduced eGFR with incident HFpEF in our study suggests 
that either or both subclinical cardiac dysfunction and 
fluid retention may have contributed to increased plasma 
volume, and thereby reduced haemoglobin levels by 
haemodilution in these SCREEN-HF participants,24 a 
possibility that is consistent with the association of loop 
diuretic therapy with incident HFpEF. The association of 
increased WCC with incident HFpEF is consistent with a 
chronic inflammatory state that may be a consequence 
of increased adipose tissue mass,25 and such a chronic 
inflammatory state may have contributed to lower 
haemoglobin levels. The association of β-blocker, statin 
and clopidogrel therapies with incident HFpEF may 
reflect the association of these therapies with underlying 
Table 3 Cox regression: multivariable subdistribution HRs
Total HF
HR (95% CI) P values
HFpEF
HR (95% CI) P values
HFrEF
HR (95% CI) P values
VHF
HR (95% CI) P values
Age (per decade) 1.9 
(1.5 to 2.4)
<0.0001 2.3 
(1.6 to 3.3)
<0.0001 1.6 
(1.1 to 2.5)
0.019
Male gender 3.1 
(1.6 to 6.0)
0.0011
DBP
(per 10 mm Hg)
0.7 
(0.5 to 0.9)
0.012
Log BMI (per 
doubling)
5.7 
(3.1 to 10.5)
<0.0001 25 
(11 to 58)
<0.0001
Waist 
circumference 
(per 10 cm)
1.29 
(1.02 to 1.62)
0.035
Hypertension 3.5 
(1.4 to 8.8)
0.0068
Diabetes 1.7 
(1.2 to 2.3)
0.0046 3.1 
(1.9 to 5.0)
<0.0001
Myocardial 
infarction
1.6 
(1.1 to 2.3)
0.0083 2.3 
(1.4 to 3.8)
0.0019 1.9 
(1.1 to 3.4)
0.029
AF 3.3 
(1.9 to 5.7)
<0.0001
OSA 1.7 
(1.1 to 2.7)
0.026
Current or former 
smoker
1.42 
(1.04 to 1.94)
0.027
Alcohol>2 drinks/
day*
2.7 
(1.4 to 5.4)
0.0047
NT-proBNP 
quintile
2.0 
(1.7 to 2.3)
<0.0001 1.8 
(1.4 to 2.3)
<0.0001 2.0 
(1.5 to 2.6)
<0.0001 1.8 
(1.3 to 2.4)
0.0003
Haemoglobin
(g/dL)
0.81 
(0.68 to 0.97)
0.023
CCB 0.56 
(0.33 to 0.95)
0.031
C statistics† 0.80 
(0.78 to 0.81)
0.78 
(0.50 to 0.85)
0.73 
(0.66 to 0.79)
0.76 
(0.72 to 0.79)
Multivariable HRs and 95% CIs for risk factors for total incident HF, HFpEF, HFrEF and VHF.
 HRs were calculated using a semiparametric proportional hazards model for the subdistribution of competing risk.14
Median (IQR) determined by the bootstrap method. 
*Refers to consumption of more than two standard drinks on any day.
†C statistics for each multivariable model were estimated for a follow-up of 5.5 years.
AF, atrial fibrillation; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; HF, heart failure; HFpEF, heart 
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, amino-terminal pro-B-type natriuretic 
peptide; OSA, obstructive sleep apnoea; VHF, valvular heart failure; WCC, white cell count. 
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vascular disease, whereas the association of NSAIDs with 
incident HFpEF is in agreement with the doubling of HF 
risk by these drugs.26
Our findings provide support for the existence of a 
distinct obese phenotype of HFpEF.24 Increased BMI 
preceded HFpEF diagnosis by a median of 4–5 years in 
the SCREEN-HF cohort, providing opportunity for inter-
vention and possible prevention of HFpEF. The many 
mechanisms that may contribute to the impaired diastolic 
filling that characterises obesity include reduced coro-
nary microvascular density consequent to cardiomyocyte 
hypertrophy.27 Although we currently have no therapies 
that improve prognosis in HFpEF, several strategies have 
been shown to improve diastolic function and may there-
fore prevent or postpone HFpEF. Blood pressure-low-
ering therapies prevent HF,28–30 and it is likely that this is 
due in part to prevention of HFpEF by reducing myocar-
dial fibrosis and LV mass, and improving diastolic func-
tion.31–34 Moreover, weight reduction in obesity reduces 
LV mass and improves diastolic function,35–37 vigorous 
physical activity is associated with reduced HF incidence 
independently of BMI38 and caloric restriction improves 
diastolic function in individuals who are not obese with 
evidence of diastolic dysfunction and ameliorates age-as-
sociated decline in diastolic function.39 40
strengths and limitations
The strengths of our study include the diagnosis of HF 
in a predominantly ambulant setting, the long dura-
tion of observation such that risk factor information was 
collected well before HF diagnosis, the separation of 
VHF from HFpEF and HFrEF and the identification of 
many risk factors for incident HFpEF. However, the large 
number of baseline variables tested for association with 
HF development was accompanied by the potential for 
type 1 error and false discovery of associations, and each 
risk factor we identified is hypothesis generating with 
respect to pathophysiological mechanisms. In addition, 
the modest number of participants who developed HF 
makes our findings susceptible to type 2 error, in that 
we cannot exclude any risk factor as a contributor to the 
pathogenesis of any of the categories of HF. Our selection 
criteria likely biased the risk factors for HF; for example, 
the high prevalence of hypertension would have reduced 
the ability of this well-recognised HF risk factor to discrim-
inate between participants. Moreover, our reliance on 
qualitative estimates of LVEF for a proportion of partici-
pants diagnosed with HFrEF prevented their subclassifi-
cation as mid-range or more severe HFrEF. Furthermore, 
despite our attempts to capture all incident cases of HF 
we may have missed some cases of early HF, and we may 
have also missed cases because we were reliant on phone 
review to pick up HF in approximately 500 participants. 
The inclusion criteria with respect to age and cardi-
ovascular risk factors, together with the SCREEN-HF 
cohort comprising volunteers who were predominantly 
members of a health fund, prevent generalisation of our 
incidence data to the general community. However, our 
inclusion criteria would have captured up to 90% of indi-
viduals in the general community at risk of HF,41 and thus 
our risk factor data are applicable to the general commu-
nity. Although baseline imaging data were incomplete 
and we may have enrolled participants with unrecognised 
LV dysfunction, including valvular dysfunction, the long 
delay in HF onset suggests that any LV dysfunction on 
enrolment was minor and likely to be subclinical. The 
echocardiographic examinations performed as part of 
the SCREEN-HF study will be the subject of future anal-
yses.
ConClusIons
We identified risk factors for incident HFpEF, HFrEF and 
VHF that preceded HF development by many years, and 
suggest that the mechanisms of HF pathogenesis were 
operating many years before HF diagnosis. Each risk 
factor we identified is hypothesis generating with respect 
to pathophysiological mechanisms of HF and potential 
therapeutic approaches. In particular, our data suggest 
a major role for BMI, hypertension, diabetes, renal 
dysfunction and inflammation in HFpEF pathogenesis. 
Strategies directed to prevention of these HFpEF risk 
factors may prevent a sizeable proportion of HFpEF in 
the community.
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